Plain-English translation of NCT06682728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a phase 2 clinical trial testing a combination of two medications—sacituzumab govitecan and —as a follow-up treatment for people who have had surgery to remove muscle-invasive bladder cancer. The study is designed for patients whose cancer has a higher-than-average risk of returning after surgery, and researchers want to see if this medication combination can help prevent recurrence.
Muscle-invasive bladder cancer can come back even after surgery removes the tumor. This medication combination represents a newer approach to treating high-risk patients after surgery, and doctors want to understand whether it can improve outcomes and reduce the chances of the cancer returning.
You likely qualify if…
You likely don't qualify if…
Over about 15 weeks, you will receive the medication combination through an IV infusion. For the first 4 weeks, you'll receive both medications together, then for the remaining 11 weeks you'll receive one of the medications () alone. You'll have regular clinic visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States